Sonova Holding AG stock faces revenue pressure after 2025 full-year results despite margin gains

Sonova Holding AG stock plunged following the release of its full-year 2025 financial results on March 23, 2026. The Swiss hearing care company reported an 8% decline in sales revenue, marking a sharp reversal from prior growth trends in the sector. This downturn reflects broader challenges in hearing aid demand, as seen in competitor Amplifon S.p.A.'s similar 4.2% revenue growth slowdown.

As of: 24.03.2026

By Elena Voss, Medtech Market Analyst: Sonova's results highlight the vulnerability of hearing care to economic pressures, yet its margin resilience positions it well for US investors seeking defensive plays in an aging population market.

Revenue Decline Signals Sector Headwinds

Sonova Holding AG, listed on the SIX Swiss Exchange under ticker SOON in CHF, disclosed its 2025 full-year figures amid a cooling market for hearing solutions. Sales fell 8% year-over-year, pressured by softening consumer demand and inventory adjustments across clinics. The company, a global leader in hearing aids and cochlear implants, operates through brands like Phonak and Unitron, serving over 120 countries.

This revenue pressure echoes industry trends, with peer Amplifon reporting just 4.2% growth after years of double-digits. Factors include higher interest rates curbing discretionary spending on premium devices and a post-pandemic normalization in hearing care visits. For Sonova, constant currency sales in the core hearing instruments business dropped, though exact figures await full audited release.

Management attributed the miss partly to weaker performance in North America and Europe, key markets comprising over 70% of revenue. US investors should note this, as Sonova derives significant exposure from its Phonak clinics and partnerships in the world's largest hearing aid market.

Margin Expansion Provides a Silver Lining

Despite the topline weakness, Sonova Holding AG stock found some support in robust profitability metrics. Adjusted EBITA margins expanded, driven by cost discipline and a favorable product mix shifting toward higher-end OTC hearing aids. This operational leverage underscores the company's competitive moat in premium audiology tech.

In the consumer hearing space, Sonova's OTC offerings like the Infinio platform gained traction, offsetting prescription device slowdowns. Gross margins held firm above historical averages, bolstered by supply chain efficiencies post-COVID disruptions. For context, peers like Amplifon also cited margin gains amid revenue pressure.

US investors benefit from Sonova's innovation pipeline, including AI-enhanced sound processing, aligning with FDA's push for accessible hearing solutions. This positions the stock as a play on demographic tailwinds, with 1 in 8 US adults affected by hearing loss.

Strategic Moves: Consumer Division Spin-Off

Sonova announced plans to separate its Consumer Hearing business, aiming to unlock value and refocus on professional audiology. This restructuring, detailed in the results release, targets listing the consumer unit independently, potentially by late 2026. The move addresses divergent growth profiles, with OTC booming while clinics face reimbursement hurdles.

For US investors, this spin-off enhances appeal. The consumer arm taps into the $10B+ OTC market unlocked by 2022 FDA rules, competing with players like WS Audiology. Sonova's 20%+ share in premium OTC positions it for gains as awareness rises among boomers.

New growth targets post-spin include mid-teens revenue CAGR for the core business, emphasizing direct-to-consumer channels. This strategic pivot responds to margin pressures from traditional clinic sales, which dropped amid staffing costs and volume softness.

US Investor Relevance in a Graying Market

Sonova Holding AG stock merits attention from US portfolios due to its outsized North American footprint, contributing ~30% of sales. The US hearing aid market, valued at $7B annually, grows at 5-7% driven by aging demographics—over-65 population to double by 2050. Sonova's Phonak brand leads in rechargeable and Bluetooth-enabled devices, capturing tech-savvy seniors.

Recent half-year data showed 4.9% sales growth in constant currency, with North America as a bright spot before the full-year slowdown. US OTC adoption accelerates, with Sonova's partnerships in retail clinics like Walmart boosting accessibility. Amid tariff talks and supply chain shifts, Sonova's Swiss base and Asian manufacturing diversify risks.

For ADR holders or ETF exposure via SMI trackers, the stock offers medtech purity without big-pharma volatility. Trading on SIX Swiss Exchange in CHF, it provides currency diversification for USD-based investors eyeing CHF strength.

Competitive Landscape and Peer Pressures

The hearing care sector faces uniform headwinds, with Sonova's 8% revenue drop mirroring Amplifon's deceleration to 4.2%. WS Audiology and Demant also grapple with clinic utilization rates below 80%, hit by economic caution. Sonova differentiates via R&D spend at 10%+ of sales, fueling platforms like myPhonak app for remote adjustments.

Market share battles intensify in OTC, where Sonova claims leadership with Infinio's AI noise reduction outperforming rivals in lab tests. However, private-label threats from big-box retailers challenge pricing power. US investors track this, as domestic players like Starkey gain from 'Made in USA' preferences.

Globally, China's volume growth offsets Western softness, but currency headwinds erode CHF-reported figures. Sonova's 2026 guidance eyes recovery via spin-off synergies and volume rebound.

Risks and Open Questions Ahead

Key risks loom for Sonova Holding AG stock. Regulatory shifts in reimbursement could squeeze clinic margins further, especially in Medicare Advantage plans popular in the US. Supply chain disruptions from Asia, amid geopolitical tensions, threaten component costs for lithium-ion batteries in devices.

The consumer spin-off carries execution risks—valuation gaps or market timing could dilute shareholder value. Demand uncertainty persists if recessions deepen, delaying premium upgrades. Analyst consensus tempers targets post-results, focusing on margin sustainability over topline.

Open questions include full P&L details, cash flow from operations, and buyback resumption. US investors weigh CHF/USD volatility, with the franc's safe-haven status buffering downside. Overall, while near-term pressure mounts, long-term demographics favor recovery.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.